Accordingly, it was suggested that PCSK9 expression could be a valuable biomarker for the clinical prognostic outcome of certain types of malignancies, including hepatocellular carcinoma, gastric, kidney, pancreas, and breast cancers (132). Here, PCSK9 is linked to breast carcinoma.